| Title | Juvenile idiopathic arthritis: an update on clinical and therapeutic approaches. | | Author(s) | Quarta L, Corrado A, Melillo N, Cantatore FP | | Institution | Clinica Reumatologica M. Carrozzo, Universiti degli Studi di Foggia. | | Source | Ann Ital Med Int 2005 Oct-Dec; 20(4):211-7. | | Abstract | Juvenile idiopathic arthritis represents a heterogeneous group of autoimmune diseases. It arises before 16 years of age and lasts more than 6 months. We can distinguish many arthritis sub-types. A serious problem in juvenile idiopathic arthritis is skeletal growth retardation, osteopenia and greater risk of developing fractures. Juvenile idiopathic arthritis diagnosis is an exclusion diagnosis. Many conditions can simulate it. First-choice drugs in juvenile idiopathic arthritis treatment are nonsteroidal anti-inflammatory drugs, analgesic and antipyretic drugs. The second-choice drugs are "slow-acting" antirheumatic drugs, like methotrexate. The use of glucocorticoids is strongly influenced by their side effects, in particular the inhibition of statural growth and the premature appearance of osteoporosis. Recent findings on the central role of tumor necrosis factor-alpha, in particular damage pathogenesis in the course of juvenile idiopathic arthritis, have permitted the development of new therapeutic strategies (infliximab, etanercept), aimed at blocking this cytokine. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 16610252 |
|
